Early trial tests 'Universal' cell injection for tough kidney diseases
NCT ID NCT07389499
Summary
This early-stage study is testing a new cell therapy called GT719 in adults with several types of immune-mediated kidney diseases that have not responded well to standard treatments. The main goals are to find a safe dose and see how well the body tolerates the treatment, while also looking for early signs that it might help control the kidney disease. About 30 participants will receive the GT719 injection and be followed for up to a year to monitor their health and kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.